^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AV-MEL-1

    i
    Other names: AV-MEL-1, AV MEL 1, autologous dendritic cells loaded with autologous tumor antigens
    Associations

    News

    Trials
    Company:
    AiVita Biomedical
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
    P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2022 --> May 2024
    Trial completion date • Trial primary completion date • Checkpoint inhibition • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    AV-MEL-1
    3years
    Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
    P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2021 --> May 2022
    Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    AV-MEL-1
    3years
    Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
    P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2021 --> May 2021
    Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    AV-MEL-1
    over3years
    Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
    P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    AV-MEL-1
    over3years
    Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
    P1b, N=20, Not yet recruiting, Aivita Biomedical, Inc. | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jun 2020 --> Oct 2021
    Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    AV-MEL-1